Lemaitre Vascular (LMAT) Change in Accured Expenses (2010 - 2026)

Lemaitre Vascular (LMAT) has 17 years of Change in Accured Expenses data on file, last reported at -$1.1 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$1.1 million, down 200.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.0 million (down 49.14% YoY), and the FY2025 annual result was $4.2 million, up 2815.28% from the prior year.
• Change in Accured Expenses climbed to -$1.1 million in Q1 2026 per LMAT's latest filing, from -$1.1 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $6.6 million in Q3 2025 and troughed at -$3.4 million in Q1 2022.
• A 5-year average of $229941.2 and a median of $35000.0 in 2022 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2023 and 2025: Change in Accured Expenses soared 9157.14% in 2023, then tumbled 884.03% in 2025.
• A 5-year view of Change in Accured Expenses shows it stood at $469000.0 in 2022, then sank by 580.38% to -$2.3 million in 2023, then soared by 106.39% to $144000.0 in 2024, then plunged by 884.03% to -$1.1 million in 2025, then rose by 4.52% to -$1.1 million in 2026.
• Business Quant data shows LMAT's Change in Accured Expenses at -$1.1 million in Q1 2026, -$1.1 million in Q4 2025, and $6.6 million in Q3 2025.